Ivarmacitinib for polymyalgia rheumatica pain and stiffness
Treatments studied
Part of Bones, joints & muscles clinical trials.
This trial tests an investigational drug, ivarmacitinib, to see if it can reduce inflammation and pain in people with polymyalgia rheumatica and help them avoid using steroids. The drug works by blocking certain immune system signals that cause joint and muscle stiffness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 75 years old.
- Your weight is between 40 and 80 kg (about 88 to 176 pounds).
- You have been diagnosed with polymyalgia rheumatica (PMR) using the 2012 ACR/EULAR classification criteria.
- Your PMR is active, as shown by a CRP-PMR-AS score of 17 or higher (this is a blood test and symptom score).
- If you are newly diagnosed, you have not used steroids in the last 12 weeks. If you have had PMR before, your steroid dose must be stable for at least 2 weeks before the trial, and you must be willing to stop steroids after the trial starts.
- You cannot have certain other autoimmune diseases (like lupus or giant cell arteritis) and no history of blood clots, active infections, or cancer in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pill, ivarmacitinib, for people with moderate-to-severe rheumatoid arthritis who have not gotten enough relief from standard treatments. It aims to reduce joint pain and swelling and improve daily life.
This study compares a new pill (ivarmacitinib) to standard steroid treatment for people with mild-to-moderate lupus. It aims to see if the new drug can better control symptoms like joint pain and skin rashes while possibly reducing steroid side effects.
This study tests a pill called Ivarmacitinib (a JAK inhibitor) for people with advanced solid tumors who had to stop immunotherapy because of side effects. The drug aims to calm the immune system and may help you restart cancer treatment.
This trial tests a new oral medication called Ivarmacitinib for people with moderate-to-severe atopic dermatitis (a type of eczema). The goal is to see if it helps reduce symptoms and improve skin condition.
This trial tests if adding baricitinib (a pill that calms inflammation) to standard steroids works better than steroids alone for people with polymyalgia rheumatica. It aims to improve symptoms and reduce steroid side effects.
This trial is testing an oral medication called ivarmacitinib, which may help protect the insulin-making cells in your pancreas and slow down the progression of type 1 diabetes. It is designed for people who have just been diagnosed with type 1 diabetes.
Hear when a new Polymyalgia Rheumatics (PMR) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.